166 related articles for article (PubMed ID: 31471463)
1. Alcohol septal ablation in patients with severe septal hypertrophy.
Veselka J; Jensen M; Liebregts M; Cooper RM; Januska J; Kashtanov M; Dabrowski M; Hansen PR; Seggewiss H; Hansvenclova E; Bundgaard H; Ten Berg J; Hilton Stables R; Faber L
Heart; 2020 Mar; 106(6):462-466. PubMed ID: 31471463
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term outcomes of alcohol septal ablation for hypertrophic obstructive cardiomyopathy in patients with mild left ventricular hypertrophy: a propensity score matching analysis.
Veselka J; Faber L; Liebregts M; Cooper R; Januska J; Kashtanov M; Dabrowski M; Hansen PR; Seggewiss H; Hansvenclova E; Bundgaard H; Ten Berg J; Stables RH; Jensen MK
Eur Heart J; 2019 Jun; 40(21):1681-1687. PubMed ID: 31152553
[TBL] [Abstract][Full Text] [Related]
3. An assessment of regression of left ventricular hypertrophy following alcohol ablation of the interventricular septum in patients with hypertrophic cardiomyopathy with left ventricular outflow tract obstruction.
Dąbrowski M; Chojnowska L; Małek L; Spiewak M; Kuśmierczyk B; Koziarek J; Klisiewicz A; Miśko J; Witkowski A
Kardiol Pol; 2012; 70(8):782-8. PubMed ID: 22933209
[TBL] [Abstract][Full Text] [Related]
4. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: results from the Euro-ASA registry.
Veselka J; Jensen MK; Liebregts M; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Tomasov P; Adlova R; Bundgaard H; Steggerda R; Ten Berg J; Faber L
Eur Heart J; 2016 May; 37(19):1517-23. PubMed ID: 26746632
[TBL] [Abstract][Full Text] [Related]
5. Outcome of Alcohol Septal Ablation in Mildly Symptomatic Patients With Hypertrophic Obstructive Cardiomyopathy: A Long-Term Follow-Up Study Based on the Euro-Alcohol Septal Ablation Registry.
Veselka J; Faber L; Liebregts M; Cooper R; Januska J; Krejci J; Bartel T; Dabrowski M; Hansen PR; Almaas VM; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg J; Stables RH; Jensen MK
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28512112
[TBL] [Abstract][Full Text] [Related]
6. Gender Disparities in Clinical Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in the Chinese Han Population: A Cohort Study.
Wang Y; Zhao HW; Wang CF; Meng QK; Cui CS; Zhang XJ; Zhu Y; Fan CY; Luo DF; Chen BJ; Luan B; Hou AJ
Heart Lung Circ; 2020 Dec; 29(12):1856-1864. PubMed ID: 32611501
[TBL] [Abstract][Full Text] [Related]
7. Reduction of left ventricular mass, left atrial size, and N-terminal pro-B-type natriuretic peptide level following alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy.
Dąbrowski M; Kukuła K; Kłopotowski M; Bekta P; Śpiewak M; Mazurkiewicz Ł; Tyczyński P; Orczykowski M; Parma R; Witkowski A
Kardiol Pol; 2019; 77(2):181-189. PubMed ID: 30566209
[TBL] [Abstract][Full Text] [Related]
8. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience.
Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM
Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561
[TBL] [Abstract][Full Text] [Related]
9. Looking back on 15 years of ultrasound-guided alcohol septal ablation for hypertrophic obstructive cardiomyopathy.
Vermaete I; Dujardin K; Stammen F
Acta Cardiol; 2020 Oct; 75(6):483-491. PubMed ID: 31204591
[No Abstract] [Full Text] [Related]
10. Outcomes of Alcohol Septal Ablation in Younger Patients With Obstructive Hypertrophic Cardiomyopathy.
Liebregts M; Faber L; Jensen MK; Vriesendorp PA; Januska J; Krejci J; Hansen PR; Seggewiss H; Horstkotte D; Adlova R; Bundgaard H; Ten Berg JM; Veselka J
JACC Cardiovasc Interv; 2017 Jun; 10(11):1134-1143. PubMed ID: 28595881
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous Intramyocardial Septal Radiofrequency Ablation for Hypertrophic Obstructive Cardiomyopathy.
Liu L; Li J; Zuo L; Zhang J; Zhou M; Xu B; Hahn RT; Leon MB; Hsi DH; Ge J; Zhou X; Zhang J; Ge S; Xiong L
J Am Coll Cardiol; 2018 Oct; 72(16):1898-1909. PubMed ID: 30309466
[TBL] [Abstract][Full Text] [Related]
12. Surgery of Hypertrophic Obstructive Cardiomyopathy in Patients With Severe Hypertrophy, Myocardial Fibrosis, and Ventricular Tachycardia.
Borisov KV
Ann Thorac Surg; 2018 Jul; 106(1):30-37. PubMed ID: 29534954
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety of transthoracic echocardiography-guided percutaneous intramyocardial septal radiofrequency ablation for the treatment of patients with obstructive hypertrophic cardiomyopathy].
Liu LW; Zuo L; Zhou MY; Li J; Zhou XD; He GB; Zhang J; Zhang JZ; Liu B; Yang J; Xu B
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Apr; 47(4):284-290. PubMed ID: 31060187
[No Abstract] [Full Text] [Related]
14. Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients.
Gietzen FH; Leuner CJ; Obergassel L; Strunk-Mueller C; Kuhn H
Heart; 2004 Jun; 90(6):638-44. PubMed ID: 15145866
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of hypertrophic obstructive cardiomyopathy patients undergoing alcohol septal ablation with a standard 3 mL dose of ethanol: Focus on long-term safety.
Kashtanov MG; Rzhannikova AD; Chernyshev SD; Kardapoltsev LV; Idov EM; Berdnikov SV; Kochmasheva VV
Catheter Cardiovasc Interv; 2020 May; 95(6):1212-1218. PubMed ID: 31566892
[TBL] [Abstract][Full Text] [Related]
16. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy.
Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J
Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes in high-risk symptomatic patients with hypertrophic cardiomyopathy undergoing alcohol septal ablation.
Kwon DH; Kapadia SR; Tuzcu EM; Halley CM; Gorodeski EZ; Curtin RJ; Thamilarasan M; Smedira NG; Lytle BW; Lever HM; Desai MY
JACC Cardiovasc Interv; 2008 Aug; 1(4):432-8. PubMed ID: 19463341
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes.
Leal S; Galeote G; Jiménez-Valero S; Sánchez-Recalde A; Salinas P; Ruiz AS; Orbe LC; Dominguéz F; Moreno R; López-Sendón JL
Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474
[TBL] [Abstract][Full Text] [Related]
19. Influence of Septal Thickness on the Clinical Outcome After Alcohol Septal Alation in Hypertrophic Cardiomyopathy.
Jensen MK; Jacobsson L; Almaas V; van Buuren F; Hansen PR; Hansen TF; Aakhus S; Eriksson MJ; Bundgaard H; Faber L
Circ Cardiovasc Interv; 2016 Jun; 9(6):. PubMed ID: 27217377
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy.
Fananapazir L; Epstein ND; Curiel RV; Panza JA; Tripodi D; McAreavey D
Circulation; 1994 Dec; 90(6):2731-42. PubMed ID: 7994815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
